Lisata Therapeutics (LSTA) director granted 30,456 restricted stock units

Rhea-AI Filing Summary

Lisata Therapeutics director granted restricted stock units

Lisata Therapeutics, Inc. director Mohammad Azab reported an award of 30,456 shares of common stock on January 9, 2026. The filing states these are restricted stock units granted under the company’s 2018 Equity Incentive Compensation Plan and that they will vest on January 9, 2027. The units were recorded at a price of $0 per share, reflecting that this was an equity grant rather than an open-market purchase.

After this grant, Azab is reported to beneficially own 104,925 shares of common stock, which the disclosure notes includes 30,456 unvested restricted stock units. The ownership is reported as held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider AZAB MOHAMMAD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	30,456	$0.00	--

Holdings After Transaction: Common Stock — 104,925 shares (Direct)

Footnotes (1)

1. Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027. Includes 30,456 unvested restricted stock units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AZAB MOHAMMAD

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC,

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		30,456(1)	A	$0	104,925(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 30,456 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 9, 2027.

2. Includes 30,456 unvested restricted stock units.

Remarks:

	James Nisco, Attorney-in-Fact for Mohammad Azab	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lisata Therapeutics (LSTA) report for Mohammad Azab?

The filing reports that director Mohammad Azab received an award of 30,456 shares of Lisata Therapeutics common stock on January 9, 2026, coded as an acquisition of non-derivative securities.

Was the Lisata Therapeutics (LSTA) insider transaction a grant or a market purchase?

The disclosure describes the 30,456 shares as restricted stock units granted under Lisata’s 2018 Equity Incentive Compensation Plan, with a reported price of $0 per share, indicating a grant rather than a market purchase.

When do Mohammad Azab’s Lisata Therapeutics (LSTA) restricted stock units vest?

The footnotes state that the 30,456 restricted stock units granted to Mohammad Azab will vest on January 9, 2027.

How many Lisata Therapeutics (LSTA) shares does Mohammad Azab beneficially own after this transaction?

Following the reported grant, Mohammad Azab is shown as beneficially owning 104,925 shares of Lisata Therapeutics common stock, which the disclosure notes includes 30,456 unvested restricted stock units.

What is Mohammad Azab’s relationship to Lisata Therapeutics (LSTA)?

The Form 4 identifies Mohammad Azab as a director of Lisata Therapeutics, Inc. and does not mark him as a 10% owner or officer.

Is the Lisata Therapeutics (LSTA) insider transaction reported as direct or indirect ownership?

The 104,925 shares beneficially owned by Mohammad Azab after the transaction are reported with an ownership form of Direct (D).